News Headlines

Is Finasteride Finally Losing Its Grip?

finasteride

Topical androgen blocking reaches Phase 3

Cosmo Pharmaceuticals has reported positive Phase 3 results for topical clascoterone 5%, positioning it as a potential treatment for male pattern hair loss. Unlike finasteride, clascoterone works locally at the scalp to block androgen activity without systemic hormonal suppression. If approved, it would represent a significant regulatory advance in male pattern hair loss treatment.